Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500681 · ClinicalTrials.gov registry record
Maintenance Plasma Exchange for Neuromyelitis Optica
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 9
- Enrollment target
NCT01500681: Completed study, sponsored by Mayo Clinic.
NCT01500681 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01500681 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly used as a rescue therapy for NMO relapses but ongoing, regular PLEX procedures (maintenance PLEX) is sometimes used to prevent relapses. This observational registry will record feasibility, tolerability, safety, and preliminary efficacy data regarding maintenance PLEX for NMO.
Interventions
- PROCEDURE Plasma exchange (PLEX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-07-09 |
What the finished NCT01500681 record still lists
NCT01500681 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Plasma exchange (PLEX) is the first listed.
NCT01500681 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01500681 about?
NCT01500681 is a clinical study titled "Maintenance Plasma Exchange for Neuromyelitis Optica". Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly used as a rescue therapy f...
What is the current status of trial NCT01500681?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2012-06. Estimated completion is 2015-07-09.
What interventions are being tested in trial NCT01500681?
The interventions under investigation include: Plasma exchange (PLEX) (PROCEDURE).
Who is sponsoring clinical trial NCT01500681?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia